Paris (France), March 28, 2015 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases today announces the appointment of Mr. Raffy Kazandjian as CEO.
Mr. Kazandijian brings over 25 years of experience in the biotechnology and venture-capital industry. Raffy has supervised over 70 investments in technology start-ups and was directly associated with several European companies such as ExonHit Therapeutics, Neurotech, Arpida, Actelion and North-American technology companies such as Cryocath Technologies. He was formerly the President of CDC-Innovation, a French venture-capital fund, from 1996 to 2002, where he raised over €250 million of capital, and was responsible for €300 million in funds under management.
He holds or has held, several board positions in life science companies, including, Arpida, Thearadiag, Cryocath (TSE : CYT), Cellectis (CLS), Immutep SA.
Raffy holds an engineering degree from the Chemistry Engineering School of Paris (ENSCP), and is a graduate from MIT (MS’85) and from the European Business School INSEAD (MBA’90).
Mr. Raffy Kazandjian said, “I am excited to be appointed the CEO of Eyevensys, a company whose EyeCET platform has the potential to radically improve the treatment of many important ophthalmic diseases. I am confident that my 25 years of experience in the biotechnology and venture-capital industry, will allow me to contribute to the successful development of Eyevensys.”